Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway ...

Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA) has approved ...

There is no cure for PIK3CA-related overgrowth spectrum, but several options are available to treat the root cause of the condition and help manage symptoms. These include targeted therapy, medication ...

Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with ...

To investigate the role of PIK3CA oncogene in tumorigenesis and development of esophageal cancer in Chinese patients at the levels of genetic mutation and epigenetics. Seventy six esophageal tumor ...

The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...

If your child has been diagnosed with a PIK3CA-related overgrowth spectrum (PROS) disease, what can you expect in daily life? These rare diseases, caused by a mutation in the PIK3CA gene, can cause a ...

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved inavolisib (Itovebi, Roche Products Limited) for adults with hormone receptor-positive (HR+), human epidermal growth ...

We evaluated the role of PIK3CA-mutations as mechanism of resistance to trastuzumab in primary HER2/neu-amplified uterine-serous-carcinoma (USC) cell lines. Fifteen whole-exome-sequenced USC cell ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Genotyping of patient tumors has been rapidly incorporated into both clinical trials and clinical practice over the last several years, with the goal of advancing personalized or precision cancer ...